Your browser doesn't support javascript.
loading
Application of rituximab in children with primary nephrotic syndrome / 医学研究生学报
Journal of Medical Postgraduates ; (12): 433-437, 2020.
Article in Zh | WPRIM | ID: wpr-821869
Responsible library: WPRO
ABSTRACT
Childhood primary nephrotic syndrome (PNS) is a challenging and persistent renal disorder. Corticosteroids is the first-line drug for the treatment of PNS. To reduce the side effects caused by the accumulation of corticosteroids dose and to maintain the remission state of the disease, immunosuppressants are applied to the treatment of PNS. However, many children with PNS still cannot get remission. Rituximab (RTX) is a novel immunosuppressive agent. In recent years, many studies have reported the treatment of PNS in children with RTX. This review analyzes the mechanism, course of treatment, dose, efficacy, and safety of RTX in the treatment of children with PNS.
Key words
Full text: 1 Index: WPRIM Language: Zh Journal: Journal of Medical Postgraduates Year: 2020 Type: Article
Full text: 1 Index: WPRIM Language: Zh Journal: Journal of Medical Postgraduates Year: 2020 Type: Article